MB# [004]

Related by string. MB# [003] . MB# [002] . MB# [001] * * KX MB# . Fujitsu MB# . m MB# . Motorola MB# . MB# MB# . MB# MFP Series . Hole MB# *

Related by context. All words. (Click for frequent words.) 67 DG# [001] 65 MB# MB# 65 DB# [003] 64 R#/MEM # 63 PSN# [002] 63 metaglidasen 63 LX# [003] 62 PS# [001] 62 ISIS # 61 orally bioavailable 61 favorable pharmacokinetic profile 61 TH# [003] 60 orally administered inhibitor 60 TRIOLEX 60 TRC# 60 HCV protease inhibitor 60 anticancer compound 60 oral prodrug 60 OXi# 60 PRT# 60 MEK inhibitor 60 preclinical efficacy 60 INT# [002] 59 preclinical studies 59 rNAPc2 59 MAP# 59 trodusquemine 59 SRT# [003] 59 Panzem R 59 vascular disrupting agent 59 INCB# [001] 59 HQK 59 selective androgen receptor modulator 59 TMC# [002] 59 Phase Ib study 59 EP# [005] 59 tezampanel 59 volociximab 58 ENMD # 58 IRX 2 58 ADL# 58 PN# [001] 58 TBC# 58 liposomal formulation 58 Xanafide 58 preclinical 58 generation purine nucleoside 58 NGX# 58 Phase IIa trials 58 ATL/TV# 58 Phenoptin 58 Triolex 58 Dapagliflozin 58 orally administered 58 Kahalalide F 58 Mipomersen 58 otelixizumab 58 CCX# 58 PLK1 SNALP 58 ATL# [001] 58 SLx 58 PEG SN# 58 preclinically 58 TG# [003] 58 Technosphere Insulin 58 JAK1 58 thymalfasin 57 mGluR5 negative 57 SPC# [001] 57 TRX# 57 Symadex 57 ARX# [001] 57 generation antisense 57 XmAb# 57 THR beta agonist 57 AEG# 57 vidofludimus 57 Menerba 57 investigational pan BCR 57 Tyrima 57 #ME# 57 PD# [005] 57 Archexin 57 ELND# 57 PEG PAL 57 KB# [002] 57 seliciclib CYC# 57 solithromycin 57 SGX# 57 selective agonist 57 PF # [001] 57 APOPTONE 57 selective inhibitor 57 Posiphen 57 Oral NKTR 57 sodium glucose cotransporter 57 RDEA# 57 HspE7 57 mertansine 57 ALN VSP 57 insulin sensitizer 57 AVN# [001] 57 TRO# 57 proteasome inhibitor 57 SPP# [001] 57 antisense drug 57 CTAP# Capsules 57 Prodarsan ® 56 antiplatelet compound 56 IMA# 56 Sym# 56 somatostatin analogue 56 XL# [003] 56 HuLuc# 56 PEG Interferon lambda 56 renin inhibitors 56 allosteric modulator 56 SCH # 56 lomitapide 56 JAK inhibitor 56 GFT# 56 epothilone 56 Apoptone 56 HE# [002] 56 MBX 56 CORT # 56 Factor VIIa 56 VRX# [002] 56 ApoB SNALP 56 ADX# 56 investigational humanized monoclonal antibody 56 eprotirome 56 Phase 2a trial 56 GV# [001] 56 iSONEP 56 teduglutide 56 R roscovitine 56 Guanilib 56 TLK# 56 Debio 56 Pimavanserin 56 alagebrium 56 KNS # 56 Azedra 56 S/GSK# 56 CRLX# 56 systemically administered 56 anticancer agent 56 TKM ApoB 56 Hsp# Inhibitor 56 potent inhibitor 56 MLN# 56 HDAC inhibitor 56 Phase 1a clinical 56 RhuDex ® 56 Phase 1b 56 polymerase inhibitor 56 angiogenesis inhibitor 56 HCV protease 56 BCX# 56 histone deacetylase HDAC inhibitor 56 TriRima 56 AP# [003] 56 Phase 2a clinical 56 PDE4 inhibitor 56 mGluR2 NAM 56 GALNS 56 ANAVEX #-# [003] 56 Radezolid 56 PEGPH# 56 radezolid 56 Synavive 56 Locteron 56 TAFA# 55 HCV polymerase inhibitors 55 protein kinase inhibitor 55 ALN TTR# 55 IND submission 55 PNP inhibitor 55 Panzem 55 Aurora kinase inhibitor 55 tanespimycin 55 Ostarine 55 pharmacokinetic profile 55 GPR# agonist 55 SERMs 55 intranasal formulation 55 Zerenex 55 Carfilzomib 55 MT# MEDI 55 Dasatinib 55 Phase #b/#a trial 55 Bezielle 55 Bruton tyrosine kinase Btk 55 Plicera 55 ATL# [002] 55 OHR/AVR# 55 AT# [001] 55 EOquin 55 Hsp# inhibitor 55 IDX# 55 RLY# 55 oral gallium 55 MYDICAR ® 55 pharmacokinetics PK 55 MYDICAR 55 HIV integrase inhibitor 55 JAK2 inhibitor 55 HepDirect 55 DP b# 55 GRNCM1 55 #D#C# 55 preclinical toxicology 55 INGN 55 humanized anti 55 pan HDAC inhibitor 55 elvitegravir 55 Onconase 55 perifosine 55 huC# DM4 55 GLPG# 55 SGLT2 55 Relivar 55 DPP4 inhibitor 55 CR# vcMMAE 55 registrational trial 55 investigational compound 55 Phase 2b clinical trials 55 Chemophase 55 ALN TTR 55 GGF2 55 davalintide 55 AERx iDMS 55 Virtex 5 55 TELINTRA 55 SAR# [002] 55 XL# XL# 55 allosteric modulator NAM 55 XP# XP# 55 XmAb 55 GKAs 55 alvespimycin 55 elotuzumab 55 ALTU 55 Genasense ® oblimersen 55 HDAC Inhibitor 55 OMP #M# 55 dipeptidyl peptidase IV 55 Zoraxel TM 55 pharmacodynamic properties 55 aldehyde dehydrogenase ALDH2 deficiency 55 bafetinib 55 HCV nucleoside polymerase inhibitors 55 ARC# [002] 55 Excellarate 55 CK # 55 muraglitazar 55 maximally tolerated dose 55 Amigal 55 Traficet EN 55 LymphoStat B TM 55 anti angiogenic agent 55 beta Estradiol 55 pharmacokinetic studies 54 Sapacitabine 54 OncoVEX GM CSF 54 resolvin 54 aleglitazar 54 LSI #P 54 phase IIa clinical 54 PRX # 54 Phase Ib 54 novel VDA molecule 54 XMT 54 QNEXA 54 nalbuphine ER 54 glucagon receptor 54 GLP toxicology studies 54 mTOR inhibitor 54 XL# XL# XL# 54 uricase 54 Vilazodone 54 CD# CEA 54 PTH analogue 54 Aflibercept 54 fosbretabulin 54 davunetide intranasal AL 54 Spiegelmer ® 54 Marqibo 54 torsemide ER 54 EGS# 54 Cleviprex TM clevidipine 54 Phase IIa clinical trials 54 CYT# 54 Tesetaxel 54 PRLX # 54 Phase IIa clinical 54 ELND-#/AZD-# 54 renin inhibitor 54 Serdaxin 54 protein tyrosine phosphatase 1B 54 NN# [001] 54 reslizumab 54 nucleotide analog 54 AZD# 54 obatoclax 54 XOMA 3AB 54 ARIKACE ™ 54 SARMs 54 ASONEP 54 CCR5 antagonist 54 Phase 2b 54 Anavex #-# 54 Bortezomib 54 GAMMAGARD 54 Phase IIb trials 54 HepDirect prodrug 54 Perifosine 54 6R BH4 54 CD# antibody [001] 54 Syncria 54 neuroprotectant 54 Aerosurf 54 pradefovir 54 CEQ# 54 PI3K/mTOR 54 nanopharmaceutical 54 leukotriene pathway 54 RH1 54 APD# 54 antiangiogenic activity 54 multiple ascending dose 54 insulin analogs 54 potent inhibition 54 EndoTAG TM -1 54 Tarceva TM 54 nitazoxanide 54 Amplimexon 54 DXL# 54 Bendavia 54 PRTX 54 Phase Ib clinical 54 novel histone deacetylase 54 CCR9 antagonist 54 BAY #-# 54 HuMax CD4 54 pramlintide 54 Elagolix 54 Elesclomol 54 Virulizin ® 54 brivaracetam 54 novel synthetic peptide 54 ganetespib 54 LNPs 54 CUDC 54 TRV# [001] 54 highly selective inhibitor 54 signal transduction inhibitor 54 targeted radiotherapeutic 54 HCD# [002] 54 cangrelor 54 Azixa 54 immunotherapeutic agent 54 Multimeric 54 omecamtiv mecarbil 54 Phase #b/#a clinical 54 HCV protease inhibitors 54 MEK inhibitors 54 humanized monoclonal antibody 54 PHX# 54 PD LID 53 JANUVIA 53 hGH CTP 53 MEK inhibitor RDEA# 53 generation URAT1 inhibitor 53 antiviral activity 53 insulin sensitizers 53 CG# [003] 53 AQ4N 53 CRx 53 Marqibo TM 53 XL# XL# XL# XL# 53 ThGRF 53 UVIDEM 53 Aurora kinase 53 deforolimus 53 brostallicin 53 JAK inhibitors 53 LY# [003] 53 selective modulator 53 custirsen 53 AKT inhibitor 53 PSN# [001] 53 cathepsin K inhibitor 53 ALN PCS 53 maturation inhibitor 53 teriflunomide 53 ProSavin 53 preclinical compounds 53 betrixaban 53 IND enabling 53 GRN#L 53 CBLC# 53 therapeutic monoclonal antibody 53 atacicept 53 Safinamide 53 Imprime PGG 53 NU# [001] 53 CYC# 53 Preclinical studies 53 Aplidin R 53 histone deacetylase inhibitor 53 NEUGENE 53 aurora kinase 53 VEGF Trap 53 Nanobody 53 AzaSite Plus 53 nanoviricides 53 SGLT2 inhibitor 53 BrachySil 53 Trofex 53 PXD# 53 PN# [003] 53 ZD# [001] 53 CoFactor 53 MAXY G# 53 Onalta 53 Reverset 53 RAV# 53 histone deacetylase HDAC 53 celgosivir 53 gallium containing 53 liprotamase 53 dose escalation Phase 53 tiapamil 53 HGS ETR1 53 docetaxel Taxotere R 53 tyrosine kinase inhibitor 53 Naproxcinod 53 Targeted Chemotherapy 53 reversible inhibitor 53 neuroprotective properties 53 Zoraxel 53 AEGR 53 HuMax EGFr 53 highly selective endothelin 53 VEGF receptor 53 Phase 2b trial 53 Protexia R 53 ALS #-# 53 Polymer Microspheres 53 Phase IIa trial 53 Exelixis compounds 53 kinase inhibitor 53 Hedgehog Pathway Inhibitor 53 Bicifadine 53 molecular imaging radiopharmaceutical 53 forodesine 53 sapacitabine 53 PROSTVAC TM 53 virus HCV protease inhibitor 53 receptor tyrosine kinase inhibitor 53 leading oral taxane 53 Elvitegravir 53 MGCD# [002] 53 bardoxolone 53 BZL# 53 Glypromate 53 RGB # 53 elacytarabine 53 FBPase 53 Hsp# inhibitors 53 VIAject 53 OvaRex R 53 2 methoxyestradiol 53 Phase 2b clinical 53 LY# [002] 53 Cloretazine ® 53 Anticalin R 53 Anticalin ® 53 vascular disrupting agents 53 proteasome inhibitors 53 RNAi therapeutic targeting 53 vivo preclinical 53 romazarit 53 peripherally acting 53 diabetic neuropathic pain 53 Miraxion 53 Aurexis 53 Allovectin 7 53 PSMA ADC 53 Fx #A 53 novel anticancer 53 LCP Tacro 53 dacetuzumab 53 Squalamine 53 AAG geldanamycin analog 53 prokinetic agent 53 Phase 2b study 53 PRX# 53 HGS# 53 JAK#/JAK# 53 LymphoStat B 53 CCR2 53 vivo efficacy 53 VAPRISOL 53 eltrombopag 53 ARC# [001] 53 MGCD# [001] 53 non nucleoside HCV 53 mRNA antagonists 53 anti CD3 53 TRIOLEX ™ 53 Candesartan 53 Phase IIa 53 mitogen activated ERK kinase 53 epigenetic therapies 53 CTA# Injection 53 nonclinical studies 53 INCB# [002] 52 Annamycin 52 sitagliptin 52 Prodarsan R 52 PBT2 52 Azedra ™ 52 NNR Therapeutics 52 talactoferrin 52 AACR NCI EORTC 52 XL# anticancer compounds 52 Targretin 52 AT# [002] 52 tranilast 52 HDL Mimetic Peptide 52 subcutaneous formulation 52 CD# monoclonal antibody 52 albiglutide 52 Phase 1b trial 52 PRO# [003] 52 lumiliximab 52 integrase inhibitor 52 anti amnesic 52 Vaxfectin 52 dexpramipexole 52 riociguat 52 oral Factor Xa 52 VA# [002] 52 Saxagliptin 52 Phase 2a clinical trials 52 pharmacodynamic 52 adecatumumab 52 ocular formulation 52 cannabinor 52 MDV# 52 insulin sensitizing 52 epothilones 52 Ceflatonin 52 hypoxia selective 52 selective kinase inhibitor 52 Relovair 52 ALGRX 52 HCV polymerase inhibitor 52 TAT# 52 potent topoisomerase II 52 nitric oxide donating prostaglandin 52 BrachySil TM 52 bile acid sequestrant 52 iroxanadine 52 orBec 52 direct renin inhibitor 52 Thiovir 52 preclinical pharmacokinetic 52 nicotinic alpha 7 52 anti angiogenic 52 FLT3 52 indiplon capsules 52 INS# [001] 52 Alocrest 52 MKC# MKC# PP 52 prodrug 52 Protelos 52 mGluR5 NAM 52 Phenserine 52 darusentan 52 Androxal TM 52 AZILECT R 52 SNALP technology 52 bevirimat 52 phase IIa 52 dyskinesia PD LID 52 orally dosed 52 TREDAPTIVE 52 plasma kallikrein inhibitor 52 MAb 52 PDE# inhibitors 52 Phase #/#a trial 52 Tofacitinib 52 Tekturna HCT 52 pitavastatin 52 AEZS 52 orally bioavailable mimics 52 inhibitor RG# 52 CA4P 52 rFIXFc 52 Trodusquemine 52 pertuzumab 52 SMT C# 52 Panzem R NCD 52 nanoviricide 52 CIMZIA ™ 52 Locteron ® 52 TACI Ig 52 vosaroxin 52 ISTODAX 52 INC# 52 Darusentan 52 Azedra TM 52 axitinib 52 Lisofylline LSF 52 Metabasis 52 sPLA2 52 PrevOnco ™ 52 corticosteroid dexamethasone 52 pharmacodynamic profile 52 BAL# [002] 52 PCK# 52 GRNVAC1 52 PEGylated interferon 52 DU #b 52 HIV integrase inhibitors 52 oral proteasome inhibitor 52 investigational monoclonal antibody 52 GLYX 52 MNTX 52 bicifadine 52 delafloxacin 52 oral rivaroxaban 52 Cycloset 52 inhaled formulation 52 Amrubicin 52 CDK inhibitor 52 Alfimeprase 52 AMR# 52 initiate Phase 1b 52 Phase 1a 52 Pharmacokinetic studies 52 favorable tolerability 52 glucokinase activator 52 imatinib Gleevec ® 52 oxymorphone ER 52 PDX pralatrexate 52 pharmacokinetic PK profile 52 Linaclotide 52 NS# [003] 52 Phase 2a Study 52 Thiarabine 52 polymerase inhibitors 52 delta isoform 52 Axona 52 TAKSTA 52 nucleoside analog 52 PI3K inhibitor 52 xanthine oxidase inhibitor 52 Fodosine 52 peginesatide 52 NVA# 52 Omacetaxine 52 FluCide 52 Phase 2a 52 AMPK activators 52 Tarvacin TM 52 TLR7 52 selective antagonist 52 Phase Ib clinical trials 52 PI3K/Akt pathway inhibitor 52 RNAi therapeutic targeting PCSK9 52 investigational drug 52 Alogliptin 52 prostone 52 QNEXA ® 52 RenaZorb TM 52 glufosfamide 52 torezolid phosphate 52 Empatic 52 angiotensin receptor blocker ARB 52 metformin sulfonylurea 52 L Annamycin 52 TG# [001] 52 tumor xenograft models 52 rALLy trial 52 Solazed TM 52 ZOLINZA 52 antithrombotic 52 alogliptin 52 MTP inhibitor 52 ocrelizumab 52 LE SN# 52 Nanobody ® 52 carfilzomib 52 P#X# antagonist 52 Muraglitazar 52 brentuximab vedotin SGN 52 intravenously administered 52 Desmoteplase 52 dosing cohort 51 Eltrombopag 51 Anticalin 51 rHuPH# 51 tivozanib 51 Ampligen ® 51 Civacir 51 BENICAR HCT 51 Vidofludimus 51 Epanova 51 Ridaforolimus 51 methylnaltrexone 51 CIMZIA TM 51 generation nucleoside analog 51 humanized antibody 51 Alzhemed TM 51 depsipeptide 51 MET amplification 51 PLX cells 51 Phase IIb clinical trials 51 rxRNA 51 aliskiren 51 JAK3 inhibitor 51 Tarvacin 51 vitro studies 51 ON #.Na 51 HDAC inhibitors 51 PREOS R 51 tocilizumab 51 PARI Pharma GmbH 51 entinostat 51 placebo controlled Phase 51 Janus Kinase 51 Randomized Phase 51 mTOR inhibitors 51 Curaxin CBLC# 51 PLX# 51 BiTE antibody 51 lurasidone 51 IL# PE#QQR 51 Cetrorelix 51 ANG# 51 Glufosfamide 51 PORxin TM platforms 51 decitabine 51 oral bioavailability 51 Kevetrin 51 preclinical pharmacology 51 LT NS# 51 MF# [002] 51 Phase #b/#a 51 UPLYSO 51 NovaBay Aganocide compounds 51 R pioglitazone HCl 51 mixed dyslipidemia 51 ularitide 51 PROCHYMAL 51 RP# [002] 51 A2 Lp PLA2 51 receptor agonist 51 Telintra 51 selective androgen receptor modulators 51 IMGN# 51 EOquin TM 51 relapsed refractory multiple myeloma 51 dose escalation trial 51 phase IIb clinical 51 tecarfarin 51 bevasiranib 51 Akt inhibitor 51 GAP #B# 51 5 HT2C receptor 51 VELCADE melphalan 51 pioglitazone HCl 51 Neuradiab 51 lintuzumab 51 Iluvien ® 51 TKB# 51 ulimorelin 51 squalamine 51 visilizumab 51 TMC# [001] 51 Shigamabs ® 51 Interferon alpha 51 MOR# 51 eculizumab 51 3 kinase PI3K 51 VitiGam 51 EPC# 51 FVIIa 51 Virulizin R 51 CRD5 51 Hycamtin ® 51 Soliris eculizumab 51 antisense inhibitors 51 Phase 2a Clinical Trial 51 TLR antagonists 51 Si#DB 51 Dr. Marlies Sproll 51 multi kinase inhibitor 51 Zybrestat 51 NXL# 51 ruxolitinib 51 Tanespimycin 51 APF# 51 donepezil Aricept 51 bazedoxifene 51 mipomersen 51 NDA resubmission 51 siRNA therapeutic 51 GED aPC 51 next generation URAT1 51 IV APAP 51 Canvaxin TM 51 Ophena TM 51 Lu AA# 51 gemcitabine Gemzar ® 51 PDE4 inhibitors 51 enzastaurin 51 Tasimelteon 51 Trofex TM 51 PORxin TM 51 DOS# 51 posaconazole 51 bexarotene 51 RSD# 51 lixisenatide 51 ATHX 51 isoform selective 51 Poly ICR 51 GATTEX 51 GRN# 51 pharmacokinetic 51 MT#/MEDI-# 51 oral renin inhibitor 51 antiviral potency 51 anti fibrotic 51 potent antitumor activity 51 recombinant biopharmaceutical 51 huN# DM1 51 antiplatelet agent 51 IL #E 51 seliciclib 51 Fibrillex TM 51 hypoxia activated prodrug 51 small molecule activators 51 Icatibant 51 HDACi 51 oral FTY# 51 BXT # 51 Valortim ® 51 valopicitabine 51 elagolix 51 Liraglutide 51 Nanobodies 51 velafermin 51 Aplidin 51 Fenretinide 51 Insegia 51 tubulin inhibitor 51 Daclizumab 51 LymphoStat B belimumab 51 PrevOnco 51 small molecule tyrosine 51 Dalbavancin 51 erlotinib Tarceva ® 51 IAP inhibitor 51 Revimmune 51 tolevamer 51 Methylnaltrexone 51 mild vasodilator 51 TASKi2 51 Valortim 51 febuxostat 51 ZYBRESTAT 51 BN# [002] 51 Aeroquin 51 vilazodone 51 R#/MEM 51 synthetic retinoid 51 PROMACTA 51 Boceprevir 51 Nanobodies ® 51 Hedgehog pathway inhibitor 51 Quinamed 51 novel topoisomerase 51 Linjeta ™ 51 preclinical models 51 therapeutic monoclonal antibodies 51 REG1 51 MultiStem 51 ONCONASE R 51 lorvotuzumab mertansine 51 midstage trials 51 CYT# potent vascular disrupting 51 sd rxRNA 51 Actilon 51 IPLEX 51 GSK # 51 PKC# 51 Stedivaze 51 XYOTAX TM 51 SU# [003] 51 stable nucleic acid 51 ongoing Phase 1b 51 vildagliptin 51 Tezampanel 51 Preclinical studies suggest 51 anticoagulant reversing agent 51 retapamulin 51 thalidomide Thalomid 51 Voreloxin 51 Parkinson disease levodopa induced 51 zonisamide SR 51 NP2 Enkephalin 51 Troxatyl 51 Zemiva TM 51 ARRY 51 vascular disrupting 51 Cethromycin 51 antisense inhibition 51 receptor antagonists 51 ONX 51 Orally administered 51 LNP formulations 50 novel prodrug 50 T#I [002] 50 multitargeted 50 investigational pharmacologically unique 50 SparVax TM 50 Aptivus ® 50 AS# amonafide L malate 50 Vicriviroc 50 tgAAC# 50 Belinostat 50 partial agonist 50 ataluren 50 selectively inhibit 50 Revascor TM 50 Lixivaptan 50 Intravenous CP 50 RG# [001] 50 mitotic kinesins 50 Darapladib 50 ARIKACE 50 CORLUX 50 Cloretazine R VNP#M 50 BRIM2 50 SinuNase TM 50 randomized discontinuation trial 50 pharmacological chaperone 50 Personalized Immunotherapy 50 CGEN # 50 investigational compounds 50 ReN# 50 IMC #B 50 Avicena 50 allosteric modulation 50 phase IIb 50 nRF#AP# 50 Eculizumab 50 tolerability profile 50 Dacogen injection 50 potently inhibit 50 trastuzumab DM1 T DM1 50 VQD 50 apremilast 50 dirucotide 50 Lubiprostone 50 Vaprisol 50 trabectedin 50 Cloretazine R 50 Aliskiren 50 NTx TM -# 50 BNC# 50 gastrin 50 EGFR HER2 50 Antiviral Activity 50 CaPre TM 50 ADVANCE PD 50 Huntexil 50 Valdoxan 50 EZN 50 Rasilez Tekturna 50 HuCAL antibodies 50 XmAb ® 50 alfimeprase 50 edoxaban 50 VLP vaccine 50 RhuDex 50 LAF# 50 BLA filing 50 Chemokine Receptor 50 bucindolol hydrochloride 50 eniluracil 50 MBP# [001]

Back to home page